CL2013000912A1 - Formulación farmaceutica liquida que comprende anticuerpos anti-receptor de interleucina-4 (il-4r). - Google Patents

Formulación farmaceutica liquida que comprende anticuerpos anti-receptor de interleucina-4 (il-4r).

Info

Publication number
CL2013000912A1
CL2013000912A1 CL2013000912A CL2013000912A CL2013000912A1 CL 2013000912 A1 CL2013000912 A1 CL 2013000912A1 CL 2013000912 A CL2013000912 A CL 2013000912A CL 2013000912 A CL2013000912 A CL 2013000912A CL 2013000912 A1 CL2013000912 A1 CL 2013000912A1
Authority
CL
Chile
Prior art keywords
interleukin
pharmaceutical formulation
liquid pharmaceutical
receptor antibodies
antibodies
Prior art date
Application number
CL2013000912A
Other languages
English (en)
Spanish (es)
Inventor
Daniel B Dix
Xiaolin Tang
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44802412&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2013000912(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of CL2013000912A1 publication Critical patent/CL2013000912A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
    • A61M5/31511—Piston or piston-rod constructions, e.g. connection of piston with piston-rod
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
    • A61M2005/2006—Having specific accessories
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/19—Constructional features of carpules, syringes or blisters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL2013000912A 2010-10-06 2013-04-04 Formulación farmaceutica liquida que comprende anticuerpos anti-receptor de interleucina-4 (il-4r). CL2013000912A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39028310P 2010-10-06 2010-10-06
US13/253,103 US8945559B2 (en) 2010-10-06 2011-10-05 Stabilized formulations containing anti-interleukin-4 receptor (IL-4R) antibodies

Publications (1)

Publication Number Publication Date
CL2013000912A1 true CL2013000912A1 (es) 2013-11-15

Family

ID=44802412

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2013000912A CL2013000912A1 (es) 2010-10-06 2013-04-04 Formulación farmaceutica liquida que comprende anticuerpos anti-receptor de interleucina-4 (il-4r).

Country Status (21)

Country Link
US (7) US8945559B2 (enExample)
EP (3) EP3354280B1 (enExample)
JP (3) JP5918246B2 (enExample)
KR (1) KR101867279B1 (enExample)
CN (2) CN106267189B (enExample)
AU (1) AU2011312191B2 (enExample)
BR (1) BR112013008366B1 (enExample)
CA (1) CA2813587C (enExample)
CL (1) CL2013000912A1 (enExample)
CY (1) CY1121233T1 (enExample)
EA (2) EA028945B1 (enExample)
IL (3) IL283424B2 (enExample)
MX (4) MX344294B (enExample)
MY (1) MY158130A (enExample)
NZ (1) NZ609557A (enExample)
PH (1) PH12013500672A1 (enExample)
PL (2) PL3354280T3 (enExample)
PT (1) PT2624865T (enExample)
SG (1) SG189220A1 (enExample)
WO (1) WO2012047954A1 (enExample)
ZA (1) ZA201302460B (enExample)

Families Citing this family (147)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
US20130064834A1 (en) 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
JP5918246B2 (ja) 2010-10-06 2016-05-18 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 抗インターロイキン−４受容体（ｉｌ−４ｒ）抗体を含有する安定化製剤
MX347602B (es) 2011-01-28 2017-05-03 Sanofi Biotechnology Composiciones farmaceuticas que comprenden anticuerpos humanos frente a pcsk9.
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
PL4252857T3 (pl) 2011-09-16 2025-03-03 Regeneron Pharmaceuticals, Inc. Sposoby redukowania poziomów lipoproteiny(a) poprzez podawanie inhibitora proproteinowej konwertazy subtylizyny keksyny-9 (pcsk9)
PT3574897T (pt) 2011-11-18 2022-04-06 Regeneron Pharma Formulação de libertação prolongada compreendendo micropartículas de proteína polimérica para utilização no vítreo do olho para o tratamento de distúrbios oculares vasculares
NZ627859A (en) 2012-01-23 2015-09-25 Regeneron Pharma Stabilized formulations containing anti-ang2 antibodies
JO3820B1 (ar) 2012-05-03 2021-01-31 Regeneron Pharma أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها
US20140004131A1 (en) 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
AR092325A1 (es) * 2012-05-31 2015-04-15 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-dll4 y kit
RU2690675C2 (ru) 2012-08-21 2019-06-05 Санофи Байотекнолоджи Способы лечения или предотвращения астмы посредством введения антагониста il-4r
US9592297B2 (en) * 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8883979B2 (en) * 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
ES2981062T3 (es) 2012-09-07 2024-10-07 Regeneron Pharma Métodos para el tratamiento de la dermatitis atópica administrando un antagonista de IL-4R
MX2015004668A (es) * 2012-10-25 2015-07-23 Medimmune Llc Formulacion estable de anticuerpos de baja viscosidad.
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
US10111953B2 (en) 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
TWI697334B (zh) 2013-06-04 2020-07-01 美商再生元醫藥公司 藉由投與ｉｌ-４ｒ抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
CA2914721A1 (en) 2013-06-07 2014-12-11 Regeneron Pharmaceuticals, Inc. Methods for inhibiting atherosclerosis by administering an inhibitor of pcsk9
EP3613432B1 (en) * 2013-06-21 2025-08-06 Sanofi Biotechnology Methods for treating nasal polyposis by administering an il-4r antagonist
TWI634900B (zh) 2013-07-11 2018-09-11 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
WO2015027154A2 (en) 2013-08-23 2015-02-26 Regeneron Pharmaceuticals, Inc. Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (sit)
JP6616298B2 (ja) 2013-11-12 2019-12-04 サノフィ・バイオテクノロジー Ｐｃｓｋ９阻害剤と共に使用するための投薬レジメン
IL315136A (en) 2014-02-21 2024-10-01 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4rantagonist
WO2015130975A1 (en) 2014-02-28 2015-09-03 Regeneron Pharmaceuticals, Inc. Methods for treating skin infection by administering an il-4r antagonist
CA2955294A1 (en) 2014-07-16 2016-01-21 Sanofi Biotechnology Methods for treating patients with heterozygous familial hypercholesterolemia (hefh)
RU2017107847A (ru) * 2014-09-03 2018-10-03 Медиммун Лимитед Стабильный состав на основе антитела к il-4r-альфа
MX2017006286A (es) 2014-11-14 2018-01-23 Sanofi Biotechnology Metodos para tratar sinusitis cronica con polipos nasales por administracion de un antagonista de il-4r.
TW202440903A (zh) 2015-08-04 2024-10-16 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法（一）
US10772956B2 (en) 2015-08-18 2020-09-15 Regeneron Pharmaceuticals, Inc. Methods for reducing or eliminating the need for lipoprotein apheresis in patients with hyperlipidemia by administering alirocumab
ES2983475T3 (es) 2016-02-19 2024-10-23 Regeneron Pharma Métodos para mejorar la eficacia de una vacuna mediante la administración de un antagonista de IL-4R
PL3448391T3 (pl) 2016-04-27 2024-09-16 AbbVie Manufacturing Management Unlimited Company Sposoby leczenia chorób, w których jest szkodliwa aktywność il-13, przy zastosowaniu przeciwciała anty-il-13
CN107474134B (zh) 2016-06-08 2021-07-27 苏州康乃德生物医药有限公司 用于结合白细胞介素4受体的抗体
EP3504328A1 (en) 2016-08-24 2019-07-03 Regeneron Pharmaceuticals, Inc. Host cell protein modification
EP4442323A3 (en) 2016-09-01 2025-01-01 Regeneron Pharmaceuticals, Inc. Methods for preventing or treating allergy by administering an il-4r antagonist
EP4345110A3 (en) 2016-09-22 2024-06-12 Regeneron Pharmaceuticals, Inc. Methods for treating severe atopic dermatitis by administering an il-4r inhibitor
US10485844B2 (en) 2016-09-22 2019-11-26 Regeneron Pharmaceuticals, Inc. Methods for treating severe atopic dermatitis by administering an IL-4R inhibitor
MY200701A (en) 2016-11-29 2024-01-11 Regeneron Pharma Method of averting opioid addiction
TWI784988B (zh) 2016-12-01 2022-12-01 美商再生元醫藥公司 治療發炎症狀的方法
WO2018118713A1 (en) 2016-12-22 2018-06-28 Regeneron Pharmaceuticals, Inc. Method of treating an allergy with allergen-specific monoclonal antibodies
JP6172880B1 (ja) * 2017-02-01 2017-08-02 協和発酵キリン株式会社 ダルベポエチンを含む液体医薬組成物
JP7630906B2 (ja) 2017-02-01 2025-02-18 イェール・ユニヴァーシティー 利尿薬耐性の治療
JOP20190260A1 (ar) * 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
WO2018204374A1 (en) 2017-05-02 2018-11-08 Merck Sharp & Dohme Corp. Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
EP3967765A1 (en) 2017-07-06 2022-03-16 FrieslandCampina Nederland B.V. Cell culture process for making a glycoprotein
WO2019028367A1 (en) 2017-08-04 2019-02-07 Regeneron Pharmaceuticals, Inc. METHODS OF TREATING ESOPHAGITIS WITH ACTIVE EOSINOPHILES
KR20250044796A (ko) 2017-10-30 2025-04-01 사노피 바이오테크놀로지 Il-4r 길항제를 투여하여 천식을 치료 또는 예방하는 방법
WO2019126123A1 (en) 2017-12-22 2019-06-27 Regeneron Pharmaceuticals, Inc. System and method for characterizing drug product impurities
MX2020006882A (es) 2018-01-05 2020-09-07 Novo Nordisk As Metodos para tratar inflamacion mediada por interleucina-6 sin inmunosupresion.
AU2019215363A1 (en) 2018-01-31 2020-07-23 Regeneron Pharmaceuticals, Inc. System and method for characterizing size and charge variant drug product impurities
TW202311746A (zh) 2018-02-02 2023-03-16 美商再生元醫藥公司 用於表徵蛋白質二聚合之系統及方法
KR20200127979A (ko) 2018-02-28 2020-11-11 리제너론 파마슈티칼스 인코포레이티드 바이러스 오염물질을 확인하기 위한 시스템 및 방법
EP4317959A3 (en) 2018-03-19 2024-03-27 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
US12253490B2 (en) 2018-03-19 2025-03-18 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
US12259355B2 (en) 2018-03-19 2025-03-25 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
TW202016125A (zh) 2018-05-10 2020-05-01 美商再生元醫藥公司 用於定量及調節蛋白質黏度之系統與方法
MA52624A (fr) 2018-05-13 2021-03-24 Regeneron Pharma Méthodes de traitement de la dermatite atopique par administration d'un inhibiteur de l'il-4r
JP7460598B2 (ja) 2018-08-10 2024-04-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 膝および／または股関節痛の安全で効果的な処置用の医薬組成物
MY204234A (en) 2018-08-27 2024-08-16 Regeneron Pharma Use of raman spectroscopy in downstream purification
BR112020026348A2 (pt) 2018-08-30 2021-03-30 Regeneron Pharmaceuticals, Inc. Método para avaliar a estequiometria e distribuição de tamanho de complexos de proteínas, para selecionar um medicamento de proteína principal e para caracterizar complexos de proteínas, e, composição farmacêutica
SG11202103907PA (en) * 2018-10-18 2021-05-28 Merck Sharp & Dohme Formulations of anti-rsv antibodies and methods of use thereof
KR20210089215A (ko) 2018-11-07 2021-07-15 머크 샤프 앤드 돔 코포레이션 항-lag3 항체 및 항-pd-1 항체의 공동-제제
US12216129B2 (en) 2018-11-09 2025-02-04 Ajou University Industry-Academic Cooperation Foundation Human antibody having high affinity to human IL-4 receptor alpha
US11312778B2 (en) 2018-11-21 2022-04-26 Brian C. Machler Method for treating allergic contact dermatitis
KR20210114927A (ko) 2019-01-16 2021-09-24 리제너론 파마슈티칼스 인코포레이티드 이황화 결합을 특징 짓는 방법
CN120241997A (zh) 2019-02-18 2025-07-04 伊莱利利公司 治疗性抗体制剂
EP3935085A1 (en) 2019-03-06 2022-01-12 Regeneron Pharmaceuticals, Inc. Il-4/il-13 pathway inhibitors for enhanced efficacy in treating cancer
CN111686247B (zh) * 2019-03-13 2022-07-29 苏州康乃德生物医药有限公司 包含人白介素-4受体α的抗体的液体组合物
PH12021552123A1 (en) 2019-03-21 2022-08-22 Regeneron Pharma Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy
TW202519263A (zh) * 2019-03-21 2025-05-16 美商再生元醫藥公司 含有抗il-33抗體之穩定調配物
EP3962515A1 (en) 2019-05-01 2022-03-09 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-33 antagonist
MX2021013519A (es) 2019-05-13 2021-12-10 Regeneron Pharma Ensayos de union de ligandos competitivos mejorados.
JP7592064B2 (ja) 2019-07-16 2024-11-29 サノフィ・バイオテクノロジー Ｉｌ－４ｒアンタゴニストを投与することにより喘息を治療するまたは予防するための方法
US11504426B2 (en) 2019-08-05 2022-11-22 Regeneron Pharmaceuticals, Inc. Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R antagonist
AU2020326713A1 (en) 2019-08-05 2022-02-17 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an il-4r antagonist
CN114667450B (zh) 2019-09-24 2025-05-02 里珍纳龙药品有限公司 用于色谱介质的使用和再生的系统及方法
US12297451B1 (en) 2019-10-25 2025-05-13 Regeneron Pharmaceuticals, Inc. Cell culture medium
US11730793B2 (en) 2019-11-25 2023-08-22 Regeneron Pharmaceuticals, Inc. Sustained release formulations using non-aqueous emulsions
BR112022011098A2 (pt) 2019-12-09 2022-09-20 Sanofi Biotechnology Métodos para tratamento de distúrbios relacionados a il-4/il-13 digitalmente identificados
EP3992974A1 (en) 2020-11-02 2022-05-04 Sanofi Biotechnology Methods for treating digitally-identified il-4/il-13 related disorders
EP4081544A1 (en) 2019-12-23 2022-11-02 Sanofi Biotechnology Methods for treating or preventing allergic asthma by administering an il-33 antagonist and/or an il-4r antagonist
EP4354145B1 (en) 2020-01-21 2025-09-17 Regeneron Pharmaceuticals, Inc. Deglycosylation methods for electrophoresis of glycosylated proteins
EP4104858A4 (en) * 2020-02-21 2023-11-29 Jiangsu Hengrui Pharmaceuticals Co., Ltd. PHARMACEUTICAL COMPOSITION CONTAINING AN ANTI-IL-4R ANTIBODY AND ITS USE
AU2021244266A1 (en) 2020-03-27 2022-12-01 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an IL-4R antagonist
IL298257A (en) 2020-05-22 2023-01-01 Regeneron Pharma Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor
CN113797331A (zh) * 2020-06-16 2021-12-17 三生国健药业（上海）股份有限公司 一种稳定的抗IL-4Rα单克隆抗体液体制剂
AU2021305093A1 (en) * 2020-07-08 2023-03-09 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-CTLA-4 antibodies
CA3192999A1 (en) 2020-08-31 2022-03-03 Regeneron Pharmaceuticals, Inc. Asparagine feed strategies to improve cell culture performance and mitigate asparagine sequence variants
AU2021357078A1 (en) 2020-10-05 2023-06-15 Regeneron Pharmaceuticals, Inc. Methods for treating asthma in pediatric subjects by administering an il-4r antagonist
KR20230113280A (ko) 2020-11-25 2023-07-28 리제너론 파마슈티칼스 인코포레이티드 비수성 멤브레인 유화법을 사용한 지속 방출 제형
CN116710124A (zh) 2020-12-17 2023-09-05 瑞泽恩制药公司 包封蛋白质的微凝胶的制造
US20220220211A1 (en) 2021-01-08 2022-07-14 Regeneron Pharmaceuticals, Inc. Methods for treating peanut allergy and enhancing peanut allergen-specific immunotherapy by administering an il-4r antagonist
US12031151B2 (en) 2021-01-20 2024-07-09 Regeneron Pharmaceuticals, Inc. Methods of improving protein titer in cell culture
AR125585A1 (es) 2021-03-03 2023-08-02 Regeneron Pharma Sistemas y métodos para cuantificar y modificar la viscosidad de proteínas
IL305901A (en) 2021-03-17 2023-11-01 Receptos Llc Methods for the treatment of atopic dermatitis using antibodies against IL-13
MX2023010794A (es) 2021-03-26 2023-10-25 Regeneron Pharma Metodos y sistemas para el desarrollo de protocolos de mezcla.
TW202304507A (zh) * 2021-04-02 2023-02-01 美商再生元醫藥公司 含有抗ｍｕｃ１６ｘ抗ｃｄ３雙特異性抗體之穩定調配物
CA3220848A1 (en) 2021-06-01 2022-12-08 Timothy Riehlman Microchip capillary electrophoresis assays and reagents
MX2024001189A (es) 2021-07-26 2024-02-27 Sanofi Biotechnology Metodos para tratar la urticaria cronica espontanea por administracion de un antagonista de il-4r.
AU2022333073A1 (en) 2021-08-23 2024-04-04 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an il-4r antagonist
CN117615785A (zh) * 2021-08-26 2024-02-27 正大天晴药业集团股份有限公司 抗il4r抗体的药物组合物及其用途
TW202326138A (zh) 2021-09-08 2023-07-01 美商再生元醫藥公司 用於定量抗體及其他含Ｆｃ蛋白之高通量及基於質譜之方法
JP2024531800A (ja) * 2021-09-20 2024-08-29 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗体の不均一性を制御する方法
KR20240090312A (ko) 2021-10-07 2024-06-21 리제너론 파아마슈티컬스, 인크. Ph 미터 보정 및 교정
TW202323817A (zh) 2021-10-07 2023-06-16 美商再生元醫藥公司 Ｐｈ建模及控制之系統及方法
KR20240099290A (ko) 2021-10-20 2024-06-28 사노피 바이오테크놀로지 Il-4r 길항제를 투여하여 결절성 양진을 치료하는 방법
CA3236367A1 (en) 2021-10-26 2023-05-04 Michelle Lafond Systems and methods for generating laboratory water and distributing laboratory water at different temperatures
US20250011408A1 (en) 2021-11-19 2025-01-09 Regeneron Pharmaceuticals, Inc. Methods and compositions for reducing centralized pain
WO2023130010A1 (en) 2021-12-30 2023-07-06 Regeneron Pharmaceuticals, Inc. Methods for attenuating atopic march by administering an il-4/il-13 antagonist
JP2025508233A (ja) 2022-03-18 2025-03-21 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ポリペプチド変異体を分析するための方法およびシステム
WO2023212586A1 (en) 2022-04-27 2023-11-02 Regeneron Pharmaceuticals, Inc. Methods for selecting patients for treatment with an ngf antagonist
WO2023215267A1 (en) * 2022-05-02 2023-11-09 Regeneron Pharmaceuticals, Inc. Anti-interleukin-4 receptor (il-4r) antibody formulations
TW202421660A (zh) 2022-07-08 2024-06-01 美商再生元醫藥公司 藉由投與il-4r拮抗劑來治療嗜伊紅性食道炎的方法
EP4580659A1 (en) 2022-08-29 2025-07-09 Sanofi Biotechnology Methods for treating chronic inducible cold urticaria by administering an il-4r antagonist
WO2024097714A1 (en) 2022-11-01 2024-05-10 Regeneron Pharmaceuticals, Inc. Methods for treating hand and foot dermatitis by administering an il-4r antagonist
IL320670A (en) 2022-11-23 2025-07-01 Regeneron Pharma Methods for enhancing bone growth by administering an IL-4R antagonist
WO2024130048A1 (en) 2022-12-16 2024-06-20 Regeneron Pharmaceuticals, Inc. Methods and systems for assessing chromatographic column integrity
US20240245779A1 (en) 2023-01-25 2024-07-25 Regeneron Pharmaceuticals, Inc. Methods of modeling liquid protein composition stability
TW202445126A (zh) 2023-01-25 2024-11-16 美商再生元醫藥公司 基於質譜法之體內共表現抗體之表徵
TW202445138A (zh) 2023-02-01 2024-11-16 美商再生元醫藥公司 用於生物巨分子分析之具質譜法的不對稱流場流分離
TW202446462A (zh) 2023-02-22 2024-12-01 美商再生元醫藥公司 系統適用性參數及管柱老化
TW202502819A (zh) 2023-03-22 2025-01-16 法商賽諾菲生物技術公司 藉由投予il-4r拮抗劑治療慢性阻塞性肺病(copd)之方法
KR20250164835A (ko) 2023-03-27 2025-11-25 리제너론 파아마슈티컬스, 인크. Il-4r 길항제를 투여하여 호산구성 위장염을 치료하는 방법
WO2024199665A1 (en) 2023-03-30 2024-10-03 Sandoz Ag Stable composition comprising a high protein concentration
TW202508625A (zh) 2023-05-01 2025-03-01 美商再生元醫藥公司 使用苯酚或苯甲醇之多劑量抗體藥物產品
CN119215163A (zh) * 2023-06-30 2024-12-31 百奥泰生物制药股份有限公司 抗IL-4Rα抗体制剂及其制备方法和应用
WO2025017034A1 (en) 2023-07-17 2025-01-23 Formycon Ag Stable liquid antibody formulation for dupilumab
WO2025054406A1 (en) 2023-09-08 2025-03-13 Regeneron Pharmaceuticals, Inc. Methods and systems for assessing chromatographic column integrity
US20250095773A1 (en) 2023-09-18 2025-03-20 Regeneron Pharmaceuticals, Inc. Methods and systems for developing chromatography protocols
WO2025072597A2 (en) 2023-09-29 2025-04-03 Regeneron Pharmaceuticals, Inc. Lyophilization using controlled nucleation
US20250108173A1 (en) 2023-10-02 2025-04-03 Regeneron Pharmaceuticals, Inc. Drug delivery device safety system
US20250129117A1 (en) 2023-10-18 2025-04-24 Regeneron Pharmaceuticals, Inc. Rapid purification of monoclonal antibody from in-process upstream cell culture material
WO2025096932A1 (en) 2023-11-02 2025-05-08 Regeneron Pharmaceuticals, Inc. Methods for reducing lipase activity using stress
WO2025116640A1 (ko) * 2023-12-01 2025-06-05 삼성바이오에피스 주식회사 항-IL-4Rα 항체의 안정한 당류-프리 액상 제형
WO2025116637A1 (ko) * 2023-12-01 2025-06-05 삼성바이오에피스 주식회사 항-IL-4Rα 항체의 안정한 액상 제형
WO2025116648A1 (ko) * 2023-12-01 2025-06-05 삼성바이오에피스 주식회사 항-IL-4Rα 항체의 안정한 완충제-프리 액상 제형
US20250230251A1 (en) 2023-12-20 2025-07-17 Bristol-Myers Squibb Company Antibodies targeting il-18 receptor beta (il-18rb) and related methods
WO2025166281A1 (en) 2024-02-01 2025-08-07 Regeneron Pharmaceuticals, Inc. Platform for charge-detection mass spectrometry analysis of aavs
WO2025175164A1 (en) 2024-02-16 2025-08-21 Regeneron Pharmaceuticals, Inc. Methods of producing concentrated formulated drug substances comprising proteins, and concentrated formulated drug substance made by the methods
WO2025194043A1 (en) 2024-03-15 2025-09-18 Regeneron Pharmaceuticals, Inc. Polysorbate and polyoxyethylene sorbitan as excipients for stable protein formulations
EP4623903A1 (en) 2024-03-28 2025-10-01 Fresenius Kabi Deutschland GmbH Pharmaceutical composition comprising dupilumab
WO2025221640A1 (en) 2024-04-15 2025-10-23 Sanofi Biotechnology Methods for treating chronic rhinosinusitis without nasal polyps by administering an il-4r antagonist
CN118105485B (zh) * 2024-04-26 2024-09-03 湖南麦济生物技术有限公司 一种稳定的抗人IL-4Rα单克隆抗体制剂
WO2025247342A1 (zh) * 2024-05-30 2025-12-04 重庆智翔金泰生物制药股份有限公司 包含抗il-4r抗体的药物组合物
WO2025259840A1 (en) 2024-06-13 2025-12-18 Regeneron Pharmaceuticals, Inc. Methods and systems for scaled chromatography

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0747045B2 (ja) 1986-10-15 1995-05-24 株式会社大協精工 積層した注射器用滑栓
JP3100727B2 (ja) 1992-01-23 2000-10-23 株式会社大協精工 変性ポリシロキサン組成物及び該組成物を被覆した衛生ゴム製品
JP3172057B2 (ja) 1995-04-05 2001-06-04 株式会社大協精工 ラミネートゴム栓
SI1516628T1 (sl) * 1995-07-27 2013-10-30 Genentech, Inc. Stabilna izotonična liofilizirana proteinska formulacija
JP3919235B2 (ja) * 1997-06-13 2007-05-23 ジェネンテク，インコーポレイテッド 抗体製剤
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
JP3512349B2 (ja) 1999-01-29 2004-03-29 株式会社大協精工 柱状ゴム要素の成形型
US6629949B1 (en) 2000-05-08 2003-10-07 Sterling Medivations, Inc. Micro infusion drug delivery device
US6659982B2 (en) 2000-05-08 2003-12-09 Sterling Medivations, Inc. Micro infusion drug delivery device
ES2382891T3 (es) 2000-05-26 2012-06-14 Immunex Corporation Uso de anticuerpos IL-4R y sus composiciones
DK1314437T3 (da) * 2000-08-11 2014-07-14 Chugai Pharmaceutical Co Ltd Stabiliserede antistofindeholdende præparater
JP2002209975A (ja) 2001-01-19 2002-07-30 Daikyo Seiko Ltd 医薬バイアル用ラミネートゴム栓
DK2335725T3 (en) * 2003-04-04 2017-01-23 Genentech Inc Highly concentrated antibody and protein formulations
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
AU2006214658A1 (en) 2005-02-02 2006-08-24 Regeneron Pharmaceuticals, Inc. Method of treating eye injury with local administration of a VEGF inhibitor
CN102614134B (zh) 2005-03-25 2016-09-07 瑞泽恩制药公司 Vegf拮抗剂制剂
WO2006138181A2 (en) * 2005-06-14 2006-12-28 Amgen Inc. Self-buffering protein formulations
RU2432155C3 (ru) 2006-06-16 2017-11-17 Ридженерон Фармасьютикалз, Инк. Составы антагониста vegf, подходящие для интравитреального введения
CN101522716B (zh) 2006-10-02 2013-03-20 瑞泽恩制药公司 抗人il-4受体的高亲和力人抗体
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
US20100189721A1 (en) * 2007-07-06 2010-07-29 Smithkline Beecham Corporation Antibody formulations
PE20091174A1 (es) * 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
PE20110302A1 (es) * 2008-09-19 2011-05-21 Hoffmann La Roche Formulacion farmaceutica de un anticuerpo contra p-selectina
WO2010042705A1 (en) * 2008-10-09 2010-04-15 Medimmune, Llc Antibody formulation
AU2010221156A1 (en) 2009-03-06 2011-09-22 Genentech, Inc. Antibody formulation
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
JP6000246B2 (ja) * 2010-08-05 2016-09-28 オーエルイーディーワークス ゲーエムベーハーＯＬＥＤＷｏｒｋｓ ＧｍｂＨ 有機エレクトロルミネッセントデバイス
JP5918246B2 (ja) 2010-10-06 2016-05-18 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 抗インターロイキン−４受容体（ｉｌ−４ｒ）抗体を含有する安定化製剤
WO2012076670A2 (en) * 2010-12-10 2012-06-14 Novartis Ag Antibody formulation
LT2704742T (lt) * 2011-05-02 2017-10-25 Millennium Pharmaceuticals, Inc. Anti-alfa4beta7 antikūno kompozicija
JP5859148B2 (ja) * 2012-03-08 2016-02-10 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ａβ抗体製剤
RU2690675C2 (ru) 2012-08-21 2019-06-05 Санофи Байотекнолоджи Способы лечения или предотвращения астмы посредством введения антагониста il-4r
ES2981062T3 (es) 2012-09-07 2024-10-07 Regeneron Pharma Métodos para el tratamiento de la dermatitis atópica administrando un antagonista de IL-4R

Also Published As

Publication number Publication date
BR112013008366B1 (pt) 2022-02-08
US20160102147A1 (en) 2016-04-14
EP3354280B1 (en) 2020-07-29
MX344294B (es) 2016-12-13
KR20130118879A (ko) 2013-10-30
EA201390494A1 (ru) 2013-09-30
NZ609557A (en) 2014-12-24
US20120097565A1 (en) 2012-04-26
US8945559B2 (en) 2015-02-03
EA028945B1 (ru) 2018-01-31
US20190367624A1 (en) 2019-12-05
ZA201302460B (en) 2014-09-25
CN103501814B (zh) 2016-09-07
US20150100030A1 (en) 2015-04-09
JP2016166218A (ja) 2016-09-15
JP5918246B2 (ja) 2016-05-18
US20180002426A1 (en) 2018-01-04
PL2624865T3 (pl) 2018-11-30
EA201791328A1 (ru) 2018-02-28
MY158130A (en) 2016-08-30
CA2813587C (en) 2019-01-15
AU2011312191A1 (en) 2013-05-02
CN106267189B (zh) 2021-02-26
US20210403581A1 (en) 2021-12-30
CN103501814A (zh) 2014-01-08
AU2011312191B2 (en) 2015-07-02
WO2012047954A1 (en) 2012-04-12
US10435473B2 (en) 2019-10-08
US20240360230A1 (en) 2024-10-31
EP2624865A1 (en) 2013-08-14
MX2019008084A (es) 2019-09-06
PL3354280T3 (pl) 2021-02-08
IL225548B (en) 2020-06-30
SG189220A1 (en) 2013-05-31
US11059896B2 (en) 2021-07-13
EP3733711A1 (en) 2020-11-04
EA034617B1 (ru) 2020-02-27
EP3354280A1 (en) 2018-08-01
IL283424A (en) 2021-06-30
IL274902B (en) 2021-06-30
CA2813587A1 (en) 2012-04-12
IL283424B1 (en) 2023-05-01
IL274902A (en) 2020-07-30
JP2013543505A (ja) 2013-12-05
US11926670B2 (en) 2024-03-12
PH12013500672A1 (en) 2013-06-03
KR101867279B1 (ko) 2018-06-15
JP6231605B2 (ja) 2017-11-15
BR112013008366A2 (pt) 2016-06-14
IL225548A0 (en) 2013-06-27
JP2018048164A (ja) 2018-03-29
MX366337B (es) 2019-07-05
PT2624865T (pt) 2018-11-05
EP2624865B1 (en) 2018-08-01
US9238692B2 (en) 2016-01-19
CN106267189A (zh) 2017-01-04
CY1121233T1 (el) 2020-05-29
MX2022014596A (es) 2023-01-11
JP6396565B2 (ja) 2018-09-26
MX2013003795A (es) 2013-06-24
IL283424B2 (en) 2023-09-01

Similar Documents

Publication Publication Date Title
CL2013000912A1 (es) Formulación farmaceutica liquida que comprende anticuerpos anti-receptor de interleucina-4 (il-4r).
DK3756652T3 (da) Stabiliserede formuleringer indeholdende anti-interleukin-6 receptor (IL-6R)-antistoffer
DK2344198T3 (da) Lipidbaserede farmaceutiske præparater til topisk anvendelse
IL211295A0 (en) Stable liquid antibody formulation
BR112015004397A2 (pt) formulações de anticorpos de receptor anti-prolactina.
IL200547A0 (en) Multiple vial drug mixing system
EP2496292A4 (en) APPARATUS FOR MEDICAMENT ADMINISTRATION
EP2730224A4 (en) ASSESSMENT AID AND ASSESSMENT APPARATUS
BR112012021455A2 (pt) formulação farmacêutica ou nutracêutica.
DK3354280T3 (da) Stabiliserede formuleringer indeholdende anti-interleukin-4-receptor- (IL-4R) antistoffer
FR2969130B1 (fr) Dispositif de distribution de liquide.
FR2963423B1 (fr) Dispositif de dosage
CL2015001237A1 (es) Anticuerpos anti-receptor de procineticinas (prokr) y usos de los mismos.
FR2958536B1 (fr) Dispositif inclinable pour cercueils
DK2477680T3 (da) Anordning til medikamentadministration
UA20275S (uk) Флакон для рідких фармацевтичних препаратів
FR2958855B1 (fr) Dispositif de diffusion d'une substance volatile
TH1201001042B (th) สูตรผสมเชิงเภสัชกรรมที่เข้มข้นสูง, ซึ่งเสถียรของแอนติ-CD20 แอนติบอดี (anti-CD20 antibody)
UA20274S (uk) Ампула для рідких фармацевтичних препаратів
FR2967989B1 (fr) Dispositif de soutirage de liquides